OGN

NEUTRALM&A

Organon & Co.

2026-07-01

Price

$13.53

-0.15%

This is the 2026-07-01 snapshot — the signals and analysis for OGN as of this single trading day.

View full OGN research hub →

Score14.5Priority

Signals5/8 DNA2/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume1.1xvs 20d avg

Analysis

Organon's (OGN) uniquely suppressed volatility and steady price action are the direct result of Sun Pharma's pending $14-per-share all-cash acquisition. Technical signals like QUIET_STORM and STEADY_CLIMB perfectly map to this M&A arbitrage dynamic, as institutional capital quietly absorbs shares to capture the remaining spread up to the $14 deal price. Furthermore, the current RISK_ON macro backdrop—highlighted by ultra-tight 0.76% credit spreads and abundant liquidity—provides supreme conviction that Sun Pharma's deal financing is secure, virtually eliminating systemic deal-break risks.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEINSIDE OUTWEAK FINISH

Key Takeaways

M&A Arbitrage Anchor: Price action is entirely dictated by the $14/share Sun Pharma acquisition, turning the stock into a low-volatility spread vehicle.
Macro-Backed Deal Security: Exceptionally tight credit spreads (0.76%) and a low VIX (16.4) remove financing risks, ensuring smooth institutional accumulation.
Standalone Value Floor: Recent pipeline expansions, including the MIUDELLA IUD rights and Canadian biosimilar launches, hedge downside risk by boosting the company's intrinsic value.

← Back to 2026-07-01 View Full OGN History →Yahoo Finance &nearr;